Literature DB >> 2997629

A caffeine analogue (1,3,7-trimethyl-6-thioxo-2-oxopurine) with a negative inotropic and chronotropic effect.

G Fassina, R M Gaion, L Caparrotta, F Carpenedo.   

Abstract

Cardiac effects of thio-xanthine derivatives, S-caffeine and S-theophylline, were studied on isolated guinea-pig atria and on partially purified cardiac cAMP phosphodiesterase enzymes. Theophylline and caffeine were taken as reference compounds. On electrically driven left atria S-caffeine (0.01-1 mmol/l) decreased contractile tension in a concentration dependent manner. On spontaneously beating atria, the same concentrations of S-caffeine showed negative inotropic as well as negative chronotropic effects. On electrically driven left atria, S-theophylline (0.01-1 mmol/l) increased heart contractile tension but, at higher concentrations, a reversal of the stimulating effect was observed. Both S-caffeine and S-theophylline inhibited bovine heart cAMP phosphodiesterase activity to a comparable extent. Their inhibitory potencies were about three and nine times higher than those of theophylline or caffeine but consistently lower than that of IBMX. The results show that the replacement of O with S in the methylxanthine molecule drastically modifies the effects induced by the drugs on cardiac function without changing those on cAMP phosphodiesterase.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2997629     DOI: 10.1007/bf00572437

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  12 in total

1.  Calcium and papaverine interaction with soluble cardiac phosphodiesterase.

Authors:  F Carpenedo; R M Gaion; G Fassina
Journal:  Biochem Pharmacol       Date:  1975-11-15       Impact factor: 5.858

2.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

3.  Assay of cyclic nucleotide phosphodiesterases with radioactive substrates.

Authors:  W J Thompson; G Brooker; M M Appleman
Journal:  Methods Enzymol       Date:  1974       Impact factor: 1.600

4.  Pharmacological actions of various inotropic agents.

Authors:  H Scholz
Journal:  Eur Heart J       Date:  1983-01       Impact factor: 29.983

5.  Adenosine antagonism by purines, pteridines and benzopteridines in human fibroblasts.

Authors:  R F Bruns
Journal:  Biochem Pharmacol       Date:  1981-02-15       Impact factor: 5.858

6.  Alkylxanthines as adenosine receptor antagonists and membrane phosphodiesterase inhibitors in central nervous tissue: evaluation of structure-activity relationships.

Authors:  P H Wu; J W Phillis; M J Nye
Journal:  Life Sci       Date:  1982-12-20       Impact factor: 5.037

7.  Evidence that the positive inotropic effects of the alkylxanthines are not due to adenosine receptor blockade.

Authors:  M G Collis; J R Keddie; S R Torr
Journal:  Br J Pharmacol       Date:  1984-02       Impact factor: 8.739

8.  New derivatives of methyl-xanthines: effect of thiocaffeine thiotheophylline and 8-phenyltheophylline on lipolysis and on phosphodiesterase activities.

Authors:  E Scotini; F Carpenedo; G Fassina
Journal:  Pharmacol Res Commun       Date:  1983-02

9.  Adenosine 3',5'-phosphate in biological materials. I. Purification and properties of cyclic 3',5'-nucleotide phosphodiesterase and use of this enzyme to characterize adenosine 3',5'-phosphate in human urine.

Authors:  R W BUTCHER; E W SUTHERLAND
Journal:  J Biol Chem       Date:  1962-04       Impact factor: 5.157

10.  The mechanism of the action of caffeine on sarcoplasmic reticulum.

Authors:  A Weber
Journal:  J Gen Physiol       Date:  1968-11       Impact factor: 4.086

View more
  1 in total

1.  Sulfur-containing 1,3-dialkylxanthine derivatives as selective antagonists at A1-adenosine receptors.

Authors:  K A Jacobson; L Kiriasis; S Barone; B J Bradbury; U Kammula; J M Campagne; S Secunda; J W Daly; J L Neumeyer; W Pfleiderer
Journal:  J Med Chem       Date:  1989-08       Impact factor: 7.446

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.